Cancer Genomics & Proteomics

474 papers and 5.7k indexed citations i.

About

The 474 papers published in Cancer Genomics & Proteomics in the last decades have received a total of 5.7k indexed citations. Papers published in Cancer Genomics & Proteomics usually cover Molecular Biology (287 papers), Cancer Research (179 papers) and Oncology (131 papers) specifically the topics of MicroRNA in disease regulation (57 papers), Cancer-related molecular mechanisms research (51 papers) and Epigenetics and DNA Methylation (45 papers). The most active scholars publishing in Cancer Genomics & Proteomics are Robert M. Hoffman, Ludmila Gorunova, Sverre Heim, Ulrich H. Weidle and Fabian Birzele.

In The Last Decade

Fields of papers published in Cancer Genomics & Proteomics

Since Specialization
EngineeringComputer SciencePhysics and AstronomyMathematicsEarth and Planetary SciencesEnergyEnvironmental ScienceMaterials ScienceChemical EngineeringChemistryAgricultural and Biological SciencesVeterinaryDecision SciencesArts and HumanitiesBusiness, Management and AccountingSocial SciencesPsychologyEconomics, Econometrics and FinanceHealth ProfessionsDentistryMedicineBiochemistry, Genetics and Molecular BiologyNeuroscienceNursingImmunology and MicrobiologyPharmacology, Toxicology and Pharmaceutics

This network shows the specialization of papers published in Cancer Genomics & Proteomics. Nodes represent fields, and links connect fields that are likely to share authors.

Countries where authors publish in Cancer Genomics & Proteomics

Since Specialization
Total citations of papers

This map shows the geographic distribution of research published in Cancer Genomics & Proteomics. It shows the number of citations received by papers published by authors working in each country. You can also color the map by specialization and compare the number of papers published in Cancer Genomics & Proteomics with the expected number of papers based on a country's size and research output (numbers larger than one mean the country's share of papers is larger than expected).

Rankless by CCL
2025